These mid-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of over 25%, according to analystNo doubt, the mood in the market has changed and the bulls seem to be back in a determined fashion. Don’t, however, expect the indices to k...
Q2 Earnings Scorecard: Which sectors outperformed and which fell behind?The September quarter results indicate strong revenue and profit growth in sectors like automobiles and banking. In contrast, sectors such ...
For long- and medium-term investors: Cycles turn, principles don’t; 5 large-cap stocks with upside potential of up to 29%These are the stocks that fell the most, so they may bounce back the most if the fund flows return. They are the ones FPI money will target...
More than family business: Drugmakers make costly, long-term strategic shifts as next generation steps into bigger rolesIndia's family-run pharmaceutical companies are entering a new phase as the next generation takes on larger leadership roles and steers bus...
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% returnIn 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic dem...
Dr Reddy's Laboratories receives ANVISA approval for generic semaglutide injection in BrazilDr Reddy’s Laboratories obtained marketing authorisation from Brazil’s ANVISA for a generic semaglutide injection. The product will be avai...
Biocon CEO forecasts H2 results to outperform H1; company posts 52% fall in Q2 net profit; revenue up 2%Biocon reported a 52% drop in second-quarter net profit due to shipment delays caused by geopolitical issues. The company expects revenue g...
Zydus Q2 profit falls 27% despite 29% revenue growth; consumer wellness sales surge 76%Zydus Lifesciences reported a 29% year-on-year rise in Q2FY27 revenue to Rs 7,909 crore, driven by growth across key markets and a 76% surg...
Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%Wockhardt has expanded its marketing access for Miqnaf in India following the removal of a supply condition. The company's biotechnology se...
Sun Pharma’s specialty portfolio, Organon deal to drive growthSun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines....
India's pharma exports rise 4.9% to USD 16.14 bn in H1; shipments to Europe up nearly 10%: PharmexcilIndia's pharmaceutical exports increased nearly 5 percent, reaching USD 16.13 billion in the first half of the fiscal year. Growth was driv...
Cancer care can be cheaper: 6 steps to cut drug costsIndia has capped trade margins at 30% on 137 non-scheduled anti-cancer drugs to reduce treatment costs. Experts call for standardised care,...
Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...
Cipla sets sights on first-wave gains from rollout of Keytruda BiosimilarCipla has partnered with Qilu Pharmaceutical to commercialize a biosimilar of Keytruda, which is a major cancer treatment. The patent for t...
Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...
Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
Dr Reddy's bets on generic semaglutide, biosimilarsDr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of gene...